Targeting mTOR globally in cancer: thinking beyond rapamycin
- PMID: 19901542
- DOI: 10.4161/cc.8.23.10070
Targeting mTOR globally in cancer: thinking beyond rapamycin
Abstract
The mammalian target of rapamycin (mTOR) is centrally involved in growth, survival and metabolism. In cancer, mTOR is frequently hyperactivated and is a clinically validated target for drug development. Until recently, we have relied largely on the use of rapamycin to study mTOR function and its anticancer potential. Recent insights now indicate that rapamycin is a partial inhibitor of mTOR through allosteric inhibition of mTOR complex-1 (mTORC1) but not mTOR complex-2 (mTORC2). Both the mechanism of action and the cellular response to mTORC1 inhibition by rapamycin and related drugs may limit the effectiveness of these compounds as antitumor agents. We and others have recently reported the discovery of second-generation ATP-competitive mTOR kinase inhibitors (TKIs) that bind to the active sites of mTORC1 and mTORC2, thereby targeting mTOR signaling function globally (reviewed in refs. 1-4). The discovery of specific, active-site mTOR inhibitors has opened a new chapter in the 40-plus year old odyssey that began with the discovery of rapamycin from a soil sample collected on Easter Island (see Vézina C, et al. J Antibiot 1975). Here, we discuss recent studies that highlight the emergence of rapamycin-resistant mTOR function in protein synthesis, cell growth, survival and metabolism. It is shown that these rapamycin-resistant mTOR functions are profoundly inhibited by TKIs. A more complete suppression of mTOR global signaling network by the new inhibitors is expected to yield a deeper and broader antitumor response in the clinic.
Similar articles
-
Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.Adv Biol Regul. 2015 Jan;57:64-74. doi: 10.1016/j.jbior.2014.09.004. Epub 2014 Sep 18. Adv Biol Regul. 2015. PMID: 25442674
-
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.J Biol Chem. 2010 Mar 12;285(11):7866-79. doi: 10.1074/jbc.M109.096222. Epub 2009 Dec 18. J Biol Chem. 2010. PMID: 20022946 Free PMC article.
-
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038. PLoS Biol. 2009. PMID: 19209957 Free PMC article.
-
Dissecting the role of mTOR: lessons from mTOR inhibitors.Biochim Biophys Acta. 2010 Mar;1804(3):433-9. doi: 10.1016/j.bbapap.2009.12.001. Epub 2009 Dec 11. Biochim Biophys Acta. 2010. PMID: 20005306 Review.
-
New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review.
Cited by
-
mTOR Inhibitors at a Glance.Mol Cell Pharmacol. 2015;7(2):15-20. Mol Cell Pharmacol. 2015. PMID: 27134695 Free PMC article.
-
Molecular damage in cancer: an argument for mTOR-driven aging.Aging (Albany NY). 2011 Dec;3(12):1130-41. doi: 10.18632/aging.100422. Aging (Albany NY). 2011. PMID: 22246147 Free PMC article.
-
The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology.Cancers (Basel). 2010 Aug 18;2(3):1576-96. doi: 10.3390/cancers2031576. Cancers (Basel). 2010. PMID: 24281174 Free PMC article.
-
Rottlerin and cancer: novel evidence and mechanisms.ScientificWorldJournal. 2012;2012:350826. doi: 10.1100/2012/350826. Epub 2012 Jan 4. ScientificWorldJournal. 2012. PMID: 22272173 Free PMC article. Review.
-
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.Blood. 2011 Jan 6;117(1):26-38. doi: 10.1182/blood-2010-04-189977. Epub 2010 Oct 12. Blood. 2011. PMID: 20940415 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous